BioNTech Draws a Line Under Tübingen and Pins Its Hopes on Madrid

BioNTech is asking shareholders to hold two very different kinds of news in their heads at once. On the operational side, the company has closed the door on a rescue bid for its Tübingen production site. On the clinical side, it is preparing a 16-abstract oncology showcase at the ESMO congress in Madrid. Between those two poles sits a share price that has been marking time.

The stock was quoted pre-market at EUR 79.45, a shade below the previous close of EUR 79.55 — a decline of 0.1%. The gap to the 52-week high of EUR 105.80 comes to 25%, a reminder of how far the market has moved from the pandemic-era enthusiasm that once carried the shares.

No Deal in Tübingen

The decision to keep Tübingen shuttered followed a bid that never became an agreement. A consortium of investors led by Peter Löw had offered up to EUR 20 million for the site, according to a Handelsblatt report. Talks collapsed, and the closure stands. The proposal, as reported by SWR citing Handelsblatt information, would have kept roughly 500 employees in work.

Management's willingness to forgo a short-term sale proceeds and absorb the shutdown instead reads as a deliberate choice to retire pandemic-era overcapacity rather than prop it up. For investors, that is a rational, if painful, step: capital and resources are being concentrated where future value is meant to come from — oncology research and development.

A Clinical Setback With Firm Boundaries

The laboratory road has proved bumpy. Last week BioNTech reported that the Phase 2/3 AHEAD-MERIT trial had failed to show a statistically significant improvement in progression-free survival. The study tested BNT113 in combination with pembrolizumab against pembrolizumab alone in HPV16-positive metastatic head and neck cancer.

The trial continues in order to assess overall survival. That cuts both ways: the disappointing result does not evaporate because the study is running on, and nor is the overall survival verdict already in. Canaccord Genuity adjusted its price target on 14 October, trimming it from $136 to $132 while keeping its buy rating, citing the BNT113 outcome. A lower target paired with a positive recommendation offers context for the setback — not a substitute for the evidence still to come.

Madrid as the Next Data Point

Attention now turns to the ESMO congress, running from 23 to 27 October in Madrid, where BioNTech plans to present 16 oncology abstracts. Among them are first Phase 2 results from the ROSETTA-Lung-107 study of pumitamig combined with docetaxel in metastatic non-small cell lung cancer, along with data on pumitamig plus elfetabart drozuntecan in advanced solid tumours. Late-stage pipeline data and further combination work will feature as well.

The volume of abstracts is no quality verdict in itself. What matters to an investor is not how crowded the programme looks but what conclusions each dataset actually supports. A scheduled presentation is, for now, a scheduled presentation — not a study success booked in advance.

Two Ledgers, One Stock

BioNTech has also set 3 November for its third-quarter 2026 results, with a company overview and a webcast conference call to follow. That date gives shareholders a separate occasion to test the financial side of their thesis, independent of the clinical headlines.

Medical evidence and financial results belong together but cannot be netted against one another. Keeping the two apart — rather than simply adding up announcements — is what turns a stream of news into a sturdier investment judgement. The Madrid presentations will have to convince on clinical grounds; the quarterly report will have to be read on its own terms.